PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
Authors
Keywords
Predictive biomarkers, PARP1 inhibitors, DNA-damaging agents, Trabectedin, Olaparib, Bone and soft tissue sarcomas, Drug synergism
Journal
Molecular Cancer
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-04-28
DOI
10.1186/s12943-017-0652-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
- (2016) E. T. Rodler et al. CLINICAL CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
- (2016) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
- (2016) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- Unique features of trabectedin mechanism of action
- (2015) Annette K. Larsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair
- (2015) S. Ying et al. CANCER RESEARCH
- Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
- (2015) Sonia Ávila-Arroyo et al. Journal of Breast Cancer
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial
- (2015) Axel Le Cesne et al. LANCET ONCOLOGY
- PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
- (2015) F. Engert et al. MOLECULAR CANCER THERAPEUTICS
- Timeless Interacts with PARP-1 to Promote Homologous Recombination Repair
- (2015) Si Xie et al. MOLECULAR CELL
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells
- (2015) Caroline V.M. Verhagen et al. RADIOTHERAPY AND ONCOLOGY
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- NF-kB signaling mediates acquired resistance after PARP inhibition
- (2015) Yuko Nakagawa et al. Oncotarget
- The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
- (2015) José Luis Ordóñez et al. Oncotarget
- TIMELESS Forms a Complex with PARP1 Distinct from Its Complex with TIPIN and Plays a Role in the DNA Damage Response
- (2015) Lauren M. Young et al. Cell Reports
- Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
- (2015) Sonja J. Gill et al. PLoS One
- Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells
- (2015) Patrick J. Grohar et al. NEOPLASIA
- Biological and clinical significance of PARP1 protein expression in breast cancer
- (2014) Andrew R. Green et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
- (2014) Jean-Yves Blay et al. EUROPEAN JOURNAL OF CANCER
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
- (2014) Maha Hussain et al. INVESTIGATIONAL NEW DRUGS
- Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
- (2014) Jung-Min Lee et al. JNCI-Journal of the National Cancer Institute
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth
- (2013) Patrick J. Grohar et al. CLINICAL CANCER RESEARCH
- Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
- (2013) R. J. Cardnell et al. CLINICAL CANCER RESEARCH
- Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice
- (2013) Thomas Helleday CURRENT OPINION IN ONCOLOGY
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
- (2013) Hae-June Lee et al. MOLECULAR CANCER THERAPEUTICS
- A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
- (2013) Stephen J. Pettitt et al. PLoS One
- Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
- (2013) P. Godwin et al. Frontiers in Oncology
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
- (2011) O A Khan et al. BRITISH JOURNAL OF CANCER
- ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma
- (2011) Antoine Italiano et al. CANCER
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers
- (2011) E. Vilar et al. CANCER RESEARCH
- Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations
- (2011) Konstantin J. Dedes et al. CELL CYCLE
- The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary
- (2011) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study
- (2011) P. Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
- (2010) P. Gottipati et al. CANCER RESEARCH
- Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
- (2010) G. Germano et al. CANCER RESEARCH
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130
- (2010) D. C. Hegan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
- (2009) X. Liu et al. MOLECULAR CANCER RESEARCH
- A Nuclear Poly(ADP-Ribose)-Dependent Signalosome Confers DNA Damage-Induced IκB Kinase Activation
- (2009) Michael Stilmann et al. MOLECULAR CELL
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk
- (2008) Tasha R. Smith et al. CARCINOGENESIS
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started